INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Core Insights - Ultragenyx is accused of misleading investors regarding the potential success of setrusumab's Phase 3 study in reducing fracture rates [1] Company Summary - The allegations suggest that Ultragenyx may have provided inaccurate information about the efficacy of setrusumab, which could impact investor confidence and stock performance [1]